Zhejiang Jiuzhou Pharmaceutical (603456) Fundamentals 2026 — P/E 20.8x, Revenue Analysis | SniperIQ
Zhejiang Jiuzhou Pharmaceutical (603456) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥13.4B, trading at ¥15.17 on the SHH. This SniperIQ fundamentals page covers Zhejiang Jiuzhou Pharmaceutical's valuation (P/E 20.8x, P/B 1.5x), profitability (net margin 12.5%), revenue (¥5.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Jiuzhou Pharmaceutical's market cap?
Zhejiang Jiuzhou Pharmaceutical (603456) has a market capitalization of approximately ¥13.4B, trading at ¥15.17 on the SHH. Market cap moves with the live share price.
What is Zhejiang Jiuzhou Pharmaceutical's P/E ratio?
Zhejiang Jiuzhou Pharmaceutical's trailing twelve-month P/E ratio is 20.8x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Jiuzhou Pharmaceutical?
Zhejiang Jiuzhou Pharmaceutical runs a net profit margin of 12.5%, a gross margin of 35.8%, and an operating margin of 15.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Jiuzhou Pharmaceutical generate?
Zhejiang Jiuzhou Pharmaceutical reported revenue of ¥5.5B for fiscal year 2025, with net income of ¥730M and earnings per share (EPS) of 0.82. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Jiuzhou Pharmaceutical pay a dividend?
Zhejiang Jiuzhou Pharmaceutical offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Jiuzhou Pharmaceutical financially healthy?
Zhejiang Jiuzhou Pharmaceutical carries a debt-to-equity ratio of 0.01x and a current ratio of 3.83x, with a market beta of 0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Jiuzhou Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Jiuzhou Pharmaceutical (603456) the key facts are: market cap ¥13.4B, P/E 20.8x, revenue ¥5.5B, 52-week range 12.05-22.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Jiuzhou Pharmaceutical's full fundamentals live
Get Zhejiang Jiuzhou Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.